Literature DB >> 14756126

Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.

Bruce L Innis, Kenneth H Eckels.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14756126     DOI： 10.4269/ajtmh.2003.69.6_suppl.0690001

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


× No keyword cloud information.
  15 in total

Review 1.  Dengue: defining protective versus pathologic immunity.

Authors:  Alan L Rothman
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  The necessity and quandaries of dengue vaccine development.

Authors:  Stephen J Thomas
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

3.  Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants.

Authors:  Veerachai Watanaveeradej; Sriluck Simasathien; Ananda Nisalak; Timothy P Endy; Richard G Jarman; Bruce L Innis; Stephen J Thomas; Robert V Gibbons; Sumetha Hengprasert; Rudiwilai Samakoses; Angkool Kerdpanich; David W Vaughn; J Robert Putnak; Kenneth H Eckels; Rafael De La Barrera; Mammen P Mammen
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

Review 4.  Recent progress in dengue vaccine development.

Authors:  Jianchun Wei; Hui Chen; Jing An
Journal:  Virol Sin       Date:  2014-12-24       Impact factor: 4.327

5.  Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys.

Authors:  David E Clements; Beth-Ann G Coller; Michael M Lieberman; Steven Ogata; Gordon Wang; Kent E Harada; J Robert Putnak; John M Ivy; Michael McDonell; Gary S Bignami; Iain D Peters; Julia Leung; Carolyn Weeks-Levy; Eileen T Nakano; Tom Humphreys
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

6.  Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.

Authors:  Jorge E Osorio; Ivan D Velez; Cynthia Thomson; Liliana Lopez; Alejandra Jimenez; Aurelia A Haller; Shawn Silengo; Jaclyn Scott; Karen L Boroughs; Janae L Stovall; Betty E Luy; John Arguello; Mark E Beatty; Joseph Santangelo; Gilad S Gordon; Claire Y-H Huang; Dan T Stinchcomb
Journal:  Lancet Infect Dis       Date:  2014-07-23       Impact factor: 25.071

7.  Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.

Authors:  Flavio Lauretti; Anasuya Chattopadhyay; Rafael Freitas de Oliveira França; Luiza Castro-Jorge; John Rose; Benedito A L da Fonseca
Journal:  Hum Vaccin Immunother       Date:  2016-05-16       Impact factor: 3.452

8.  Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice.

Authors:  Shuo Zhang; Mifang Liang; Wen Gu; Chuan Li; Fang Miao; Xiaofang Wang; Cong Jin; Li Zhang; Fushun Zhang; Quanfu Zhang; Lifang Jiang; Mengfeng Li; Dexin Li
Journal:  Virol J       Date:  2011-06-30       Impact factor: 4.099

9.  Biological and Molecular Properties of Dengue 2 Strains Isolated during the DHF/DSS Cuban Epidemic, 1981.

Authors:  Lester González; Mayling Alvarez; Delfina Del Rosario; Alequis Pavón; Irina Prado; Joel Díaz; Luis Morier; María G Guzmán
Journal:  Int J Biomed Sci       Date:  2007-06

10.  A phase II, randomized, safety and immunogenicity study of a re-derived, live-attenuated dengue virus vaccine in healthy adults.

Authors:  Stephen J Thomas; Kenneth H Eckels; Isabelle Carletti; Rafael De La Barrera; Francis Dessy; Stefan Fernandez; Robert Putnak; Jean-Francois Toussaint; Wellington Sun; Kristen Bauer; Robert V Gibbons; Bruce L Innis
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.